Free Trial
NASDAQ:MGRX

Mangoceuticals (MGRX) Stock Price, News & Analysis

Mangoceuticals logo
$2.37
-0.10 (-4.05%)
(As of 10/31/2024 ET)

About Mangoceuticals Stock (NASDAQ:MGRX)

Key Stats

Today's Range
$2.31
$2.59
50-Day Range
$2.37
$67.14
52-Week Range
$2.14
$16.80
Volume
195,140 shs
Average Volume
243,572 shs
Market Capitalization
$4.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

Mangoceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
32nd Percentile Overall Score

MGRX MarketRank™: 

Mangoceuticals scored higher than 32% of companies evaluated by MarketBeat, and ranked 848th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mangoceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mangoceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mangoceuticals has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mangoceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.63% of the float of Mangoceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Mangoceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Mangoceuticals has recently decreased by 79.63%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Mangoceuticals does not currently pay a dividend.

  • Dividend Growth

    Mangoceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.63% of the float of Mangoceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Mangoceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Mangoceuticals has recently decreased by 79.63%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Mangoceuticals has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Mangoceuticals this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for MGRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Mangoceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mangoceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    39.30% of the stock of Mangoceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    56.72% of the stock of Mangoceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mangoceuticals' insider trading history.
Receive MGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mangoceuticals and its competitors with MarketBeat's FREE daily newsletter.

MGRX Stock News Headlines

Analyzing Mangoceuticals (MGRX) & Its Competitors
Head to Head Review: Mangoceuticals (MGRX) versus Its Rivals
Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
Mangoceuticals (MGRX) and Its Rivals Head to Head Analysis
Head to Head Analysis: Mangoceuticals (MGRX) & Its Rivals
Mangoceuticals (MGRX) and Its Peers Financial Review
See More Headlines

MGRX Stock Analysis - Frequently Asked Questions

Mangoceuticals' stock was trading at $62.3025 at the beginning of 2024. Since then, MGRX shares have decreased by 96.2% and is now trading at $2.39.
View the best growth stocks for 2024 here
.

Mangoceuticals, Inc. (NASDAQ:MGRX) released its earnings results on Wednesday, August, 14th. The company reported ($20.25) earnings per share for the quarter. The business had revenue of $0.16 million for the quarter. Mangoceuticals had a negative net margin of 1,053.93% and a negative trailing twelve-month return on equity of 243.34%.

Mangoceuticals's stock reverse split on Wednesday, October 16th 2024. The 1-15 reverse split was announced on Wednesday, October 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Mangoceuticals (MGRX) raised $5 million in an IPO on Tuesday, March 21st 2023. The company issued 1,300,000 shares at $4.00 per share. Boustead Securities acted as the underwriter for the IPO.

Mangoceuticals' top institutional shareholders include Ackerman Capital Advisors LLC (3.52%). Insiders that own company stock include Jacob D Cohen and Alex P Hamilton.
View institutional ownership trends
.

Shares of MGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mangoceuticals investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), MSP Recovery (LIFW), MSP Recovery (LIFW), Palantir Technologies (PLTR) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
8/14/2024
Today
10/31/2024
Next Earnings (Estimated)
11/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
Healthcare
Current Symbol
NASDAQ:MGRX
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-9,210,000.00
Net Margins
-1,053.93%
Pretax Margin
-1,053.81%

Debt

Sales & Book Value

Annual Sales
$866,792.00
Book Value
$0.54 per share

Miscellaneous

Free Float
1,211,000
Market Cap
$4.77 million
Optionable
Not Optionable
Beta
1.76
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:MGRX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners